<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Microbiol. InfectClinical Microbiology and Infection1198-743X1469-0691European Society of Clinical Microbiology and" exact="Infectious" post="Diseases. Published by Elsevier Ltd. pmcid: 7250111S1198-743X(20)30293-7 doi: 10.1016/j.cmi.2020.05.016"/>
 <result pre="2020-5-5268979987received: 2020-4-8rev-recd: 2020-5-5accepted: 2020-5-16(C) European Society of Clinical Microbiology and" exact="Infectious" post="Diseases, 2020Since January 2020 Elsevier has created a COVID-19"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="agents is a re-emerging topic with the advent of new" exact="viral" post="epidemics. Aims To summarize evidence from human clinical studies"/>
 <result pre="for using HCQ or CQ as antiviral agents for any" exact="viral infection." post="Sources PubMed, EMBASE, Scopus, Web of Science for published"/>
 <result pre="control group). Participants were adults and children with a confirmed" exact="viral infection." post="Interventions included the use of CQ or HCQ as"/>
 <result pre="two preprints) were eligible (HIV 8, HCV 2, dengue 2," exact="chikungunya" post="1, COVID-19 6). Nine and ten studies assessed CQ"/>
 <result pre="assessed CQ and HCQ respectively. Benefits of either drug for" exact="viral" post="load suppression in HIV are inconsistent. CQ is ineffective"/>
 <result pre="evidence) and may have little or no benefit in curing" exact="chikungunya" post="(low-certainty evidence). The evidence for COVID-19 infection is rapidly"/>
 <result pre="benefit in curing chikungunya (low-certainty evidence). The evidence for COVID-19" exact="infection" post="is rapidly evolving but at this stage we are"/>
 <result pre="viraemia (very-low-certainty evidence). Implications Using HCQ or CQ for HIV/HCV" exact="infections" post="is now clinically irrelevant as other effective antivirals are"/>
 <result pre="now clinically irrelevant as other effective antivirals are available for" exact="viral" post="load suppression (HIV) and cure (HCV). There is no"/>
 <result pre="is beneficial in COVID-19 infection. Keywords Antivirals Chikungunya Chloroquine COVID-19" exact="Dengue" post="Hydroxychloroquine Pneumonia Editor: M. Paul Introduction With the advent"/>
 <result pre="in COVID-19 infection. Keywords Antivirals Chikungunya Chloroquine COVID-19 Dengue Hydroxychloroquine" exact="Pneumonia" post="Editor: M. Paul Introduction With the advent of the"/>
 <result pre="Paul Introduction With the advent of the pandemic of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19), repurposing cheap"/>
 <result pre="Introduction With the advent of the pandemic of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19), repurposing cheap and"/>
 <result pre="With the advent of the pandemic of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) disease (COVID-19), repurposing cheap and accessible"/>
 <result pre="the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="disease" post="(COVID-19), repurposing cheap and accessible drugs for off-label use"/>
 <result pre="countries. The antiviral properties of CQ were first explored against" exact="viral hepatitis" post="as far back as 1963 [1]. Since then many"/>
 <result pre="The antiviral properties of CQ were first explored against viral" exact="hepatitis" post="as far back as 1963 [1]. Since then many"/>
 <result pre="have suggested a beneficial role of HCQ and CQ in" exact="viral" post="infections [[2], [3], [4], [5], [6], [7], [8], [9],"/>
 <result pre="suggested a beneficial role of HCQ and CQ in viral" exact="infections" post="[[2], [3], [4], [5], [6], [7], [8], [9], [10],"/>
 <result pre="drugs is used as a mainstream antiviral agent for any" exact="viral infection." post="This review focuses on the clinical evidence for using"/>
 <result pre="for using CQ and HCQ as antiviral agents against any" exact="viral infection." post="This reflection and summary of evidence is needed in"/>
 <result pre="use of these drugs. Even when such evidence may be" exact="incomplete" post="or unavailable for emerging infections such as COVID-19, historical"/>
 <result pre="when such evidence may be incomplete or unavailable for emerging" exact="infections" post="such as COVID-19, historical attempts for repurposing these agents"/>
 <result pre="COVID-19, historical attempts for repurposing these agents for other emerging" exact="viral" post="infections from time to time may draw parallels with"/>
 <result pre="historical attempts for repurposing these agents for other emerging viral" exact="infections" post="from time to time may draw parallels with the"/>
 <result pre="and non-controlled), including case series, were considered, but case reports" exact="limited" post="to single patients were excluded. Retrospective studies and animal"/>
 <result pre="experiments were excluded. Participants Adults or children with a confirmed" exact="viral infection" post="were included. Intervention and comparator All participants (non-controlled studies)"/>
 <result pre="were excluded. Participants Adults or children with a confirmed viral" exact="infection" post="were included. Intervention and comparator All participants (non-controlled studies)"/>
 <result pre="controlled studies were standard treatment, no treatment, or placebo. Outcomes" exact="Primary" post="outcome was viral load suppression for chronic infections and"/>
 <result pre="standard treatment, no treatment, or placebo. Outcomes Primary outcome was" exact="viral" post="load suppression for chronic infections and clearance of viraemia"/>
 <result pre="or placebo. Outcomes Primary outcome was viral load suppression for" exact="chronic" post="infections and clearance of viraemia for acute infections. Any"/>
 <result pre="placebo. Outcomes Primary outcome was viral load suppression for chronic" exact="infections" post="and clearance of viraemia for acute infections. Any other"/>
 <result pre="load suppression for chronic infections and clearance of viraemia for" exact="acute" post="infections. Any other significant outcomes (depending on the type"/>
 <result pre="were extracted from each included study: study design and location," exact="viral infection" post="and diagnostic criteria, participant demographics, intervention and control groups"/>
 <result pre="extracted from each included study: study design and location, viral" exact="infection" post="and diagnostic criteria, participant demographics, intervention and control groups"/>
 <result pre="participant demographics, intervention and control groups (if any), drug doses," exact="primary" post="and secondary outcomes, and adverse events attributable to therapy."/>
 <result pre="intervention and control groups (if any), drug doses, primary and" exact="secondary" post="outcomes, and adverse events attributable to therapy. A meta-analysis"/>
 <result pre="risk of bias. Certainty of evidence was assessed for each" exact="infection" post="(only from randomized controlled trials, RCTs) according to the"/>
 <result pre="above None None None EMBASE As above None None None" exact="CENTRAL" post="â€œhydroxychloroquineâ€� or â€œchloroquineâ€� None None 2015â€&quot;2020 Any unpublished/incomplete trial"/>
 <result pre="to have been published within this time frame Results A" exact="total" post="of 2267 abstract results were found from all databases"/>
 <result pre="abstract. The studies included randomized and non-randomized controlled trials and" exact="uncontrolled" post="prospective studies equivalent to case series. These had tested"/>
 <result pre="had tested the efficacy of CQ and HCQ in human" exact="immunodeficiency" post="virus (HIV), dengue, chikungunya, hepatitis C and COVID-19 infections."/>
 <result pre="CQ and HCQ in human immunodeficiency virus (HIV), dengue, chikungunya," exact="hepatitis C" post="and COVID-19 infections. A meta-analysis was not performed due"/>
 <result pre="Fig.Â 2 . The results are discussed separately for each" exact="infection" post="and under each section; randomized clinical trials are discussed"/>
 <result pre="clinical trials are discussed first, followed by other study designs." exact="Chronic" post="infections (HIV/HCV) are discussed first as the aim of"/>
 <result pre="trials are discussed first, followed by other study designs. Chronic" exact="infections" post="(HIV/HCV) are discussed first as the aim of treatment"/>
 <result pre="(HIV/HCV) are discussed first as the aim of treatment is" exact="viral" post="load suppression rather than cure. Details of study design"/>
 <result pre="all examining the role of HCQ and CQ in COVID-19" exact="infection" post="(TableÂ 3 ). Fig.Â 1 PRISMA flow diagram of"/>
 <result pre="Placebo for same duration (nÂ =Â 20) Significant decrease in" exact="viral" post="load in HCQ group (p 0.022)No change in absolute"/>
 <result pre="mg/d for same duration (nÂ =Â 37) Significant decrease in" exact="viral" post="load in both HCQ (p 0.02) and zidovudine groups"/>
 <result pre="cell count in HCQ group (p 0.03)Greater increase in HIV" exact="viral" post="load in HCQ group (pÂ High risk of attrition"/>
 <result pre="2002, Singapore [24] Non-controlled prospective study HIV-infected patients with a" exact="viral" post="load &amp;lt;105 copies/Î¼L and CD4+ cell countÂ &amp;gt;Â 150/Î¼L"/>
 <result pre="to bodyweight for 48Â weeks (nÂ =Â 22) Decline in" exact="viral" post="load by an average of 1.3 logs with sustained"/>
 <result pre="an average of 1.3 logs with sustained CD4+ cell level" exact="Neutropenia" post="and elevated amylase levels noted in a majority of"/>
 <result pre="for 24Â weeks No significant difference in the drop of" exact="viral" post="load or increase in CD4+ cell count between the"/>
 <result pre="the on-ART cohort. CQ also led to an increase in" exact="viral" post="RNA load High risk of attrition bias â€&quot; 13%"/>
 <result pre="2016, Egypt [27] Randomized, prospective, single-blind, controlled study Patients with" exact="chronic" post="active HCV (genotype 4) infection with chronic hepatitis on"/>
 <result pre="single-blind, controlled study Patients with chronic active HCV (genotype 4)" exact="infection" post="with chronic hepatitis on liver biopsy but without decompensated"/>
 <result pre="study Patients with chronic active HCV (genotype 4) infection with" exact="chronic hepatitis" post="on liver biopsy but without decompensated liver disease Group"/>
 <result pre="Patients with chronic active HCV (genotype 4) infection with chronic" exact="hepatitis" post="on liver biopsy but without decompensated liver disease Group"/>
 <result pre="infection with chronic hepatitis on liver biopsy but without decompensated" exact="liver disease" post="Group 1: pegylated interferon (IFN) 160 Î¼g subcutaneously weeklyÂ"/>
 <result pre="with chronic hepatitis on liver biopsy but without decompensated liver" exact="disease" post="Group 1: pegylated interferon (IFN) 160 Î¼g subcutaneously weeklyÂ"/>
 <result pre="8Â weeks or placebo (nÂ =Â 10) Significant decrease in" exact="viral" post="RNA (p 0.04) after 8Â weeks This is a"/>
 <result pre="trial and method of sample size calculation is unclearRebound of" exact="viral" post="RNA noted after stopping CQ Dengue Tricou etÂ al.,"/>
 <result pre="calculation is unclearRebound of viral RNA noted after stopping CQ" exact="Dengue" post="Tricou etÂ al., 2010, Vietnam [28] Randomized, double-blind, placebo-controlled"/>
 <result pre="Islands 2008 [30] Randomized, double-blind, placebo-controlled trial Patients with confirmed" exact="acute" post="chikungunya infection by RT-PCR and seroconversion between day 1"/>
 <result pre="2008 [30] Randomized, double-blind, placebo-controlled trial Patients with confirmed acute" exact="chikungunya" post="infection by RT-PCR and seroconversion between day 1 and"/>
 <result pre="[30] Randomized, double-blind, placebo-controlled trial Patients with confirmed acute chikungunya" exact="infection" post="by RT-PCR and seroconversion between day 1 and 16"/>
 <result pre="at day 200. However, they might have had more severe" exact="disease" post="at enrolment as revealed later by an analysis of"/>
 <result pre="Chen etÂ al. China, 2020 [36] Randomized controlled clinical trial" exact="Adult" post="patients with virologically confirmed (RT-PCR) mild COVID-19 infection Group"/>
 <result pre="clinical trial Adult patients with virologically confirmed (RT-PCR) mild COVID-19" exact="infection" post="Group 1: HCQ 400 mg/d for 5Â days plus"/>
 <result pre="clearance of viraemia by day 7, fever clearance time or" exact="total" post="duration of hospitalization Article is published in MandarinOnly the"/>
 <result pre="Gautret etÂ al. France, 2020 [35] Open-label, non-randomized, controlled trial" exact="Adult" post="patients with virologically confirmed (RT-PCR) COVID-19 infection as test"/>
 <result pre="non-randomized, controlled trial Adult patients with virologically confirmed (RT-PCR) COVID-19" exact="infection" post="as test groupSimilar patients treated at a different institution"/>
 <result pre="etÂ al. China, 2020 [38] Randomized double-blind controlled clinical trial" exact="Adult" post="patients with virologically confirmed (RT-PCR) mild COVID-19 infection Group"/>
 <result pre="clinical trial Adult patients with virologically confirmed (RT-PCR) mild COVID-19" exact="infection" post="Group 1: HCQ 400 mg/d for 5Â days plus"/>
 <result pre="interpreted Tang etÂ al. China, 2020 [37] Open-label randomized trial" exact="Adult" post="patients with virologically confirmed (RT-PCR) mostly mild COVID-19 infection"/>
 <result pre="trial Adult patients with virologically confirmed (RT-PCR) mostly mild COVID-19" exact="infection" post="Group 1: HCQ 200 mg/d for 3Â days followed"/>
 <result pre="al. China, 2020 [40] Randomized controlled clinical trial (open label?)" exact="Adult" post="patients with virologically confirmed (RT-PCR) COVID-19 infection Group 1:"/>
 <result pre="trial (open label?) Adult patients with virologically confirmed (RT-PCR) COVID-19" exact="infection" post="Group 1: CQ 600 mg base/d for 10Â daysGroup"/>
 <result pre="Borba etÂ al. Brazil, 2020 [41] Randomized controlled double-blind study" exact="Adult" post="patients with clinically suspected COVID-19 infection Group 1: CQ"/>
 <result pre="Randomized controlled double-blind study Adult patients with clinically suspected COVID-19" exact="infection" post="Group 1: CQ 1200 mg base/d for 10Â daysGroup"/>
 <result pre="CQ, chloroquine; HCQ, hydroxychloroquine. aRisk of bias not assessed for" exact="uncontrolled" post="studies as results from these studies were not used"/>
 <result pre="Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus" exact="disease" post="(COVID-19) NCT04307693 ClinicalTrials.gov Chloroquine prevention of coronavirus disease (COVID-19)"/>
 <result pre="mild coronavirus disease (COVID-19) NCT04307693 ClinicalTrials.gov Chloroquine prevention of coronavirus" exact="disease" post="(COVID-19) in the healthcare setting NCT04303507 ClinicalTrials.gov Treatment of"/>
 <result pre="control trial NCT04303299 ClinicalTrials.gov New treatment for radical cure of" exact="dengue fever" post="with antiviral and anti-cytokine CTRI/2017/12/010834 WHO ICTRP A prospective,"/>
 <result pre="or hydroxychloroquine in patients with mild and common novel coronavirus" exact="pulmonary" post="(COVID-19) ChiCTR2000030054 Chinese Clinical Trials Registry A prospective, randomized,"/>
 <result pre="for chloroquine and hydroxychloroquine in patients with severe novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000029992 Chinese Clinical Trials Registry Evaluation the efficacy"/>
 <result pre="phosphate chloroquine in mild and common patients with novel coronavirus" exact="pneumonia" post="(COVID-19): a randomized, open-label, parallel, controlled trial ChiCTR2000029899 Chinese"/>
 <result pre="comparison with phosphate chloroquine in severe patients with novel coronavirus" exact="pneumonia" post="(COVID-19): a randomized, open-label, parallel, controlled trial ChiCTR2000029898 Chinese"/>
 <result pre="hydroxychloroquine on close contacts after exposure to the novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000029803 Chinese Clinical Trials Registry A multicenter, single-blind,"/>
 <result pre="trial for chloroquine phosphate in the treatment of novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000031204 Chinese Clinical Trials Registry A randomized controlled"/>
 <result pre="combine with chloroquine phosphate in the treatment of novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000030987 Chinese Clinical Trials Registry Randomized controlled trial"/>
 <result pre="trial for chloroquine phosphate in the treatment of novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000030718 Chinese Clinical Trials Registry Clinical study of"/>
 <result pre="of chloroquine phosphate in the treatment of severe novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000029988 Chinese Clinical Trials Registry Single arm study"/>
 <result pre="chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000029975 Chinese Clinical Trials Registry A single-blind, randomized,"/>
 <result pre="trial for chloroquine phosphate in the treatment of novel coronavirus" exact="pneumonia" post="2019 (COVID-19) ChiCTR2000029939 Chinese Clinical Trials Registry A single-arm"/>
 <result pre="trial for chloroquine phosphate in the treatment of novel coronavirus" exact="pneumonia" post="2019 (COVID-19) ChiCTR2000029935 Chinese Clinical Trials Registry Efficacy of"/>
 <result pre="the efficacy of chloroquine phosphate in patients with novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000029609 Chinese Clinical Trials Registry Study for the"/>
 <result pre="for the efficacy of chloroquine in patients with novel coronavirus" exact="pneumonia" post="(COVID-19) ChiCTR2000029542 Chinese Clinical Trials Registry aThe names were"/>
 <result pre="or zidovudine [18]. Two RCTs reported a significant decrease in" exact="viral" post="load with no change in absolute CD4 cell count"/>
 <result pre="while the third RCT [20] recorded a significant increase in" exact="viral" post="load and a decrease in the CD4 cell count"/>
 <result pre="decrease in the CD4 cell count with HCQ. The two" exact="uncontrolled" post="studies were small (nÂ =Â 20â€&quot;22) and used HCQ"/>
 <result pre="hydroxyurea plus didanosine [24]. There was a modest reduction in" exact="viral" post="load after 48Â weeks with combination therapy [24], while"/>
 <result pre="in all studies. CQ for HIV Two double-blind RCTs enrolled" exact="adult" post="patients with HIV (CQ 150â€&quot;300 mg base/d, 8â€&quot;12Â weeks)"/>
 <result pre="placebo [21,22] or zidovudine plus didanosine (paediatric trial) [19]. Both" exact="adult" post="trials enrolled patients with a CD4 cell count of"/>
 <result pre="one trial which had a complex cross-over design, the HIV" exact="viral" post="load increased when CQ was administered without any other"/>
 <result pre="but significantly more gastrointestinal adverse events were observed with CQ." exact="Hepatitis" post="C Use of CQ or HCQ for HCV infection"/>
 <result pre="CQ. Hepatitis C Use of CQ or HCQ for HCV" exact="infection" post="has been evaluated in two RCTs, one a single-blinded"/>
 <result pre="IFN and ribavirin therapy, and noted a significant drop in" exact="viral" post="RNA levels following 8Â weeks of therapy (p 0.04),"/>
 <result pre="nor CQ has been evaluated in combination with these agents." exact="Dengue" post="Two studies had assessed CQ for dengue infection (none"/>
 <result pre="these agents. Dengue Two studies had assessed CQ for dengue" exact="infection" post="(none assessed HCQ). A double-blind RCT (nÂ =Â 307)"/>
 <result pre="group) [29]. There was no statistically significant difference in the" exact="total" post="duration of illness or adverse events. Chikungunya Chikungunya is"/>
 <result pre="duration of illness or adverse events. Chikungunya Chikungunya is a" exact="viral" post="illness endemic in the tropics. Acute infection mimics a"/>
 <result pre="Chikungunya Chikungunya is a viral illness endemic in the tropics." exact="Acute" post="infection mimics a viral flu and sometimes leads to"/>
 <result pre="Chikungunya is a viral illness endemic in the tropics. Acute" exact="infection" post="mimics a viral flu and sometimes leads to a"/>
 <result pre="viral illness endemic in the tropics. Acute infection mimics a" exact="viral" post="flu and sometimes leads to a debilitating, persistent inflammatory"/>
 <result pre="a viral flu and sometimes leads to a debilitating, persistent" exact="inflammatory arthritis." post="There was only one RCT that had evaluated CQ"/>
 <result pre="evaluated CQ as an antiviral agent (none evaluated HCQ) in" exact="acute" post="chikungunya infection. This double-blind RCT, conducted in French Reunion"/>
 <result pre="CQ as an antiviral agent (none evaluated HCQ) in acute" exact="chikungunya" post="infection. This double-blind RCT, conducted in French Reunion Islands"/>
 <result pre="RCT, conducted in French Reunion Islands in 2006, enrolled 54" exact="adult" post="patients with virologically confirmed acute chikungunya infection to receive"/>
 <result pre="Islands in 2006, enrolled 54 adult patients with virologically confirmed" exact="acute" post="chikungunya infection to receive either CQ (600 mg of"/>
 <result pre="in 2006, enrolled 54 adult patients with virologically confirmed acute" exact="chikungunya" post="infection to receive either CQ (600 mg of base/day"/>
 <result pre="2006, enrolled 54 adult patients with virologically confirmed acute chikungunya" exact="infection" post="to receive either CQ (600 mg of base/day for"/>
 <result pre="and MCP-1 in the group that received CQ (more severe" exact="disease" post="at baseline and hence increased likelihood of persistent arthralgia)"/>
 <result pre="as a DMARD, HCQ is potentially useful to treat chikungunya-induced" exact="chronic" post="arthritis. A randomized controlled trial evaluated HCQ for this"/>
 <result pre="A randomized controlled trial evaluated HCQ for this purpose after" exact="acute" post="chikungunya infection [33]. However, as HCQ was not â€˜repurposedâ€™"/>
 <result pre="randomized controlled trial evaluated HCQ for this purpose after acute" exact="chikungunya" post="infection [33]. However, as HCQ was not â€˜repurposedâ€™ as"/>
 <result pre="controlled trial evaluated HCQ for this purpose after acute chikungunya" exact="infection" post="[33]. However, as HCQ was not â€˜repurposedâ€™ as an"/>
 <result pre="scope of this review. SARS-CoV-2 The ongoing epidemic of SARS-CoV-2" exact="disease" post="(referred to as COVID -19) is rapidly evolving. Potential"/>
 <result pre="is rapidly evolving. Potential use of CQ for COVID-19 associated" exact="pneumonia" post="first emerged in February 2020 based on several Chinese"/>
 <result pre="times daily for 10Â days to treat patients with COVID-19-associated" exact="pneumonia" post="[34]. We could not verify the evidence for this"/>
 <result pre="any of the databases searched and was identified from a" exact="secondary" post="bibliography search. It describes a randomized clinical trial (NCT04261517)"/>
 <result pre="a throat swab) by day 7, fever clearance time, and" exact="total" post="duration of hospital stay were similar between the two"/>
 <result pre="patients also received azithromycin) and all had radiological evidence of" exact="pneumonia" post="(CT scan). The control group (nÂ =Â 16) was"/>
 <result pre="time to aviraemia or symptom resolution by day 28. Many" exact="secondary" post="outcomes proposed in methodsâ€&quot;including all-cause mortalityâ€&quot;are not reported in"/>
 <result pre="and randomized 62 virologically confirmed COVID-19 patients with evidence of" exact="pneumonia" post="on CT scan to receive HCQ (400 mg/d for"/>
 <result pre="days) or no HCQ treatment (31 in each group). The" exact="respiratory" post="distress was not severe (PaO2/FIO2 &amp;gt;300 or SaO2/SPO2 &amp;gt;93%)"/>
 <result pre="in 31 patients in each group. The recruits had severe" exact="infection" post="at the time of enrolment as defined by tachycardia,"/>
 <result pre="currently recommended as an antiviral agent for any of the" exact="infections" post="for which they were tested in clinical trials (with"/>
 <result pre="evolving situation at the time of writing). The most researched" exact="infection" post="in this regard is HIV. However, mainstream antiretroviral treatment"/>
 <result pre="However, mainstream antiretroviral treatment in HIV is highly successful in" exact="viral" post="load suppression, allowing reasonable control of the disease though"/>
 <result pre="successful in viral load suppression, allowing reasonable control of the" exact="disease" post="though it is not a cure. These newer combinations"/>
 <result pre="do such tests. The same can be said of HCV" exact="infection" post="where pan-genotypic direct-acting antiviral agents can now achieve &amp;gt;90%"/>
 <result pre="rates with minimum adverse events [42]. Repurposing HCQ/CQ for these" exact="infections" post="is largely redundant and of historical interest only. In"/>
 <result pre="largely redundant and of historical interest only. In contrast, for" exact="acute" post="viral infections such as dengue, chikungunya or COVID-19, effective"/>
 <result pre="redundant and of historical interest only. In contrast, for acute" exact="viral" post="infections such as dengue, chikungunya or COVID-19, effective antivirals"/>
 <result pre="and of historical interest only. In contrast, for acute viral" exact="infections" post="such as dengue, chikungunya or COVID-19, effective antivirals are"/>
 <result pre="only. In contrast, for acute viral infections such as dengue," exact="chikungunya" post="or COVID-19, effective antivirals are not available. These infections"/>
 <result pre="dengue, chikungunya or COVID-19, effective antivirals are not available. These" exact="infections" post="cause epidemics in vulnerable populations, exerting an enormous financial"/>
 <result pre="exerting an enormous financial burden on resource-limited healthcare systems. For" exact="dengue fever," post="given the evidence presented here we conclude that CQ"/>
 <result pre="bias. CQ may have little or no effect in curing" exact="acute" post="chikungunya infection (low-certainty evidence) and this conclusion is supported"/>
 <result pre="CQ may have little or no effect in curing acute" exact="chikungunya" post="infection (low-certainty evidence) and this conclusion is supported by"/>
 <result pre="may have little or no effect in curing acute chikungunya" exact="infection" post="(low-certainty evidence) and this conclusion is supported by a"/>
 <result pre="trial which may have inadvertently recruited people with more severe" exact="disease" post="to the CQ arm despite randomization. For COVID-19 we"/>
 <result pre="most patients with COVID-19 (&amp;gt;95%) will recover after a mild" exact="infection" post="regardless of antiviral treatment. Therefore, the primary outcome assessed"/>
 <result pre="after a mild infection regardless of antiviral treatment. Therefore, the" exact="primary" post="outcome assessed in this study (clearance of viraemia) is"/>
 <result pre="demonstrate a benefit in the more severe end of the" exact="disease" post="spectrum, such as mortality benefit, reduction in intensive care"/>
 <result pre="days) was much higher than that used for cure of" exact="malaria" post="which is the standard indication for CQ. Mortality was"/>
 <result pre="animal studies for more than five decades and in a" exact="limited" post="number of human clinical studies spanning over 25Â years."/>
 <result pre="longer relevant as other effective treatments are now available for" exact="viral" post="load suppression (HIV) or cure (HCV). There is good"/>
 <result pre="is good evidence that CQ is ineffective in curing dengue" exact="infection" post="or preventing dengue haemorrhagic fever. CQ also may not"/>
 <result pre="fever. CQ also may not have any benefit in curing" exact="acute" post="chikungunya infection. A role for HCQ or CQ in"/>
 <result pre="CQ also may not have any benefit in curing acute" exact="chikungunya" post="infection. A role for HCQ or CQ in COVID-19"/>
 <result pre="funding were received for this study. References References 1Pareja-CoronelA.Treatment of" exact="viral hepatitis" post="with chloroquineAm J Gastroenterol39196328829813941394 2KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.InÂ vitro inhibition of"/>
 <result pre="were received for this study. References References 1Pareja-CoronelA.Treatment of viral" exact="hepatitis" post="with chloroquineAm J Gastroenterol39196328829813941394 2KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.InÂ vitro inhibition of"/>
 <result pre="with chloroquineAm J Gastroenterol39196328829813941394 2KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.InÂ vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun323200426426815351731 3VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine"/>
 <result pre="chloroquineAm J Gastroenterol39196328829813941394 2KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.InÂ vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem Biophys Res Commun323200426426815351731 3VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is"/>
 <result pre="J Gastroenterol39196328829813941394 2KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.InÂ vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem Biophys Res Commun323200426426815351731 3VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a"/>
 <result pre="Res Commun323200426426815351731 3VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J22005 4De ClercqE.Potential antivirals and antiviral strategies"/>
 <result pre="chloroquine and its hydroxyl analogue to face bacterial, fungal and" exact="viral" post="infections in the 21st centuryInt J Antimicrob Ag302007297308 6SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects"/>
 <result pre="and its hydroxyl analogue to face bacterial, fungal and viral" exact="infections" post="in the 21st centuryInt J Antimicrob Ag302007297308 6SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of"/>
 <result pre="the 21st centuryInt J Antimicrob Ag302007297308 6SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: an old drug against today's diseases?Lancet Infect Dis3200372272714592603"/>
 <result pre="Rep72017 11AkpovwaH.Chloroquine could be used for the treatment of filoviral" exact="infections" post="and other viral infections that emerge or emerged from"/>
 <result pre="be used for the treatment of filoviral infections and other" exact="viral" post="infections that emerge or emerged from viruses requiring an"/>
 <result pre="used for the treatment of filoviral infections and other viral" exact="infections" post="that emerge or emerged from viruses requiring an acidic"/>
 <result pre="infectivityCell Biochem Funct34201619119627001679 12BarclayW.LongJ.WrightE.MolestiE.TempertonN.Antiviral therapies against Ebola and other emerging" exact="viral" post="diseases using existing medicines that block virus entryF1000 Res42015"/>
 <result pre="and strength of recommendationsBMJ336200892418436948 17SperberK.LouieM.KrausT.PronerJ.SapiraE.LinS.Hydroxychloroquine treatment of patients with human" exact="immunodeficiency" post="virus type 1Clin Ther1719956226368565026 18SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.Comparison of hydroxychloroquine with zidovudine"/>
 <result pre="of hydroxychloroquine with zidovudine in asymptomatic patients infected with human" exact="immunodeficiency" post="virus type 1Clin Ther1919979139239385480 19EngchanilC.KosalaraksaP.LumbiganonP.LulitanondV.PongjunyakulP.ThuennadeeR.Therapeutic potential of chloroquine added"/>
 <result pre="Med Assoc Thai8920061229123617048434 20PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.Effects of hydroxychloroquine on immune activation and" exact="disease" post="progression among HIV-infected patients not receiving antiretroviral therapy: a"/>
 <result pre="Hum Retroviruses32201663664726935044 22MurrayS.M.DownC.M.BoulwareD.R.StaufferW.M.CavertW.P.SchackerT.W.Reduction of immune activation with chloroquine therapy during" exact="chronic" post="HIV infectionJÂ Virol842010120821208620844049 23PiconiS.ParisottoS.RizzardiniG.PasseriniS.TerziR.ArgenteriB.Hydroxychloroquine drastically reduces immune activation in"/>
 <result pre="of chloroquine on some clinical and biochemical parameters in non-response" exact="chronic hepatitis C" post="virus infection patients: pilot clinical trialActa Biomed8720164653 26PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.New use"/>
 <result pre="chloroquine on some clinical and biochemical parameters in non-response chronic" exact="hepatitis C" post="virus infection patients: pilot clinical trialActa Biomed8720164653 26PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.New use"/>
 <result pre="some clinical and biochemical parameters in non-response chronic hepatitis C" exact="virus infection" post="patients: pilot clinical trialActa Biomed8720164653 26PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.New use of an"/>
 <result pre="clinical and biochemical parameters in non-response chronic hepatitis C virus" exact="infection" post="patients: pilot clinical trialActa Biomed8720164653 26PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.New use of an"/>
 <result pre="trialActa Biomed8720164653 26PeymaniP.YeganehB.SabourS.GeramizadehB.FattahiM.R.KeyvaniH.New use of an old drug: chloroquine reduces" exact="viral" post="and ALT levels in HCV non-responders (a randomized, triple-blind,"/>
 <result pre="early virological response to pegylated interferon plus ribavirin in genotype-4" exact="chronic hepatitis C" post="patientsJÂ Med Virol8820162170217827183377 28TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.AÂ randomized controlled trial of chloroquine"/>
 <result pre="virological response to pegylated interferon plus ribavirin in genotype-4 chronic" exact="hepatitis C" post="patientsJÂ Med Virol8820162170217827183377 28TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.AÂ randomized controlled trial of chloroquine"/>
 <result pre="29BorgesM.C.CastroL.A.FonsecaB.A.Chloroquine use improves dengue-related symptomsMem Inst Oswaldo Cruz108201359659923903975 30De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On" exact="chikungunya" post="acute infection and chloroquine treatmentVector Borne Zoonotic Dis8200883783918620511 31de"/>
 <result pre="use improves dengue-related symptomsMem Inst Oswaldo Cruz108201359659923903975 30De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On chikungunya" exact="acute" post="infection and chloroquine treatmentVector Borne Zoonotic Dis8200883783918620511 31de LamballerieX.NinoveL.CharrelR.N.Antiviral"/>
 <result pre="improves dengue-related symptomsMem Inst Oswaldo Cruz108201359659923903975 30De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On chikungunya acute" exact="infection" post="and chloroquine treatmentVector Borne Zoonotic Dis8200883783918620511 31de LamballerieX.NinoveL.CharrelR.N.Antiviral treatment"/>
 <result pre="and chloroquine treatmentVector Borne Zoonotic Dis8200883783918620511 31de LamballerieX.NinoveL.CharrelR.N.Antiviral treatment of" exact="chikungunya" post="virus infectionInfect Disord Drug Targets9200910110419275698 32RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of chloroquine"/>
 <result pre="Disord Drug Targets9200910110419275698 32RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of chloroquine treatment in enhancing" exact="chikungunya" post="virus infectionViruses102018 33RavindranV.AliasG.Efficacy of combination DMARD therapy vs. hydroxychloroquine"/>
 <result pre="infectionViruses102018 33RavindranV.AliasG.Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in" exact="chronic" post="persistent chikungunya arthritis: a 24-week randomized controlled open label"/>
 <result pre="of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent" exact="chikungunya" post="arthritis: a 24-week randomized controlled open label studyClin Rheumatol3620171335134027699657"/>
 <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
 <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA"/>
 <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA Netw"/>
 <result pre="42SpenglerU.Direct antiviral agents (DAAs)â€&quot;a new age in the treatment of" exact="hepatitis C" post="virus infectionPharmacol Ther183201811812629024739"/>
</results>
